232 related articles for article (PubMed ID: 28274233)
1. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
[TBL] [Abstract][Full Text] [Related]
2. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
[TBL] [Abstract][Full Text] [Related]
3. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
[TBL] [Abstract][Full Text] [Related]
5. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
[TBL] [Abstract][Full Text] [Related]
6. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
[TBL] [Abstract][Full Text] [Related]
7. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
[No Abstract] [Full Text] [Related]
8. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I.
Adam BW; Lim TH; Hall EM; Hannon WH
Clin Chem; 2009 Dec; 55(12):2207-13. PubMed ID: 19850631
[TBL] [Abstract][Full Text] [Related]
9. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
[TBL] [Abstract][Full Text] [Related]
10. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
[TBL] [Abstract][Full Text] [Related]
11. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program.
Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB
Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696
[TBL] [Abstract][Full Text] [Related]
12. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
13. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots.
Allard P; Grenier A; Korson MS; Zytkovicz TH
Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530
[TBL] [Abstract][Full Text] [Related]
14. Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.
Schlump JU; Mayatepek E; Spiekerkoetter U
Eur J Pediatr; 2010 May; 169(5):569-72. PubMed ID: 19813022
[TBL] [Abstract][Full Text] [Related]
15. Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia.
Weigel JF; Janzen N; Pfäffle RW; Thiery J; Kiess W; Ceglarek U
J Inherit Metab Dis; 2007 Aug; 30(4):610. PubMed ID: 17694358
[TBL] [Abstract][Full Text] [Related]
16. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.
Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D
Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422
[TBL] [Abstract][Full Text] [Related]
17. Newborn screening for Tyr-I: two years' experience of the New York State program.
Morrissey MA; Sunny S; Fahim A; Lubowski C; Caggana M
Mol Genet Metab; 2011 Jun; 103(2):191-2. PubMed ID: 21441051
[TBL] [Abstract][Full Text] [Related]
18. Newborn Screening for Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase and Mitochondrial Trifunctional Protein Deficiencies Using Acylcarnitines Measurement in Dried Blood Spots-A Systematic Review of Test Accuracy.
Stinton C; Fraser H; Geppert J; Johnson R; Connock M; Johnson S; Clarke A; Taylor-Phillips S
Front Pediatr; 2021; 9():606194. PubMed ID: 33816395
[No Abstract] [Full Text] [Related]
19. Evaluation of factors influencing accuracy in the analysis of succinylacetone in dried blood spots.
Peng M; Liu L; Peng L
Clin Chim Acta; 2012 Aug; 413(15-16):1265-9. PubMed ID: 22522056
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
